Larry Green (Ablexis)

Larry Green is CEO and founder of Ablexis, co-inventor of the AlivaMab Mouse. He also serves as CEO of AlivaMab Discovery Services.

[Larry Green (Ablexis) @AblexisLarry]

Thrilled to see Eli Lilly and Company expanding their existing license of the #AlivaMabMouse platform. @LillyPad

Full release here: https://t.co/MNmMkq3B4Q

[Larry Green (Ablexis) @AblexisLarry]

Interested in the learning about the selection of antibody discovery platform? View this on-demand webinar here: https://t.co/JkYz86XHmZ #AntibodyDiscovery #AlivaMabDiscoveryServices

[Larry Green (Ablexis) @AblexisLarry]

Happy to announce this Licensing Agreement with Allogene Therapeutics (@AllogeneTx) as they work towards the advancement of CAR T therapies for cancer: https://t.co/gTnIkmAOmw

[Tatiana Prowell, MD @tmprowell]

Looking for a current list of all #FDAOncology drug approvals in #hematology & #oncology? Here you go: https://t.co/z2WbfnNx42. In chronological order & each concise listing contains a link to more info, including press release, package insert, etc. #MedEd

[Edelman @EdelmanPR]

Why biotech has a trust advantage over #pharma https://t.co/GrHlMotjUJ via @PharmExec

[Larry Green (Ablexis) @AblexisLarry]

Thrilled to have the opportunity to be interviewed in @PharmExec recently. Read the full story here: https://t.co/4tx4Ro2VKH

[cafepharma @cafepharma]

Merck, Amgen back a $30M play for Ribometrix — one of the upstarts making its mark in drugging RNA: The idea that you can drug RNA has attracted a variety of biotech startups interested in pioneering a new technology. And one of those biotechs looking to… https://t.co/Vd7NngEVr8

[Larry Green (Ablexis) @AblexisLarry]

Happy to announce this progress in our Intellectual Property on #AlivaMabMouse and Immunoglobulin Locus Engineering. Read more here: https://t.co/wv99LXBDvp

[Larry Green (Ablexis) @AblexisLarry]

Excited to have delivered a webinar with the team at Nature on considerations for choosing an #AntibodyDiscovery platform and the long-term, strategic implications. You can view the webinar on demand at https://t.co/5xdW73AIQt

[cafepharma @cafepharma]

Biotech's big-bucks buybacks begin to burn: If big biotech cannot deliver innovation investors might start demanding shareholder payout plans that look more like big pharma's. https://t.co/Te0ys4d4zY

[Larry Green (Ablexis) @AblexisLarry]

Thrilled that an antibody discovered using #AlivaMabMouse has entered clinical development! Read more here: https://t.co/qPWGl27e9c

[Tatiana Prowell, MD @tmprowell]

Have you been told you have a variant of uncertain significance in a gene on #genetictesting? It might be worth checking periodically w/ the company to see if it’s been reclassified. cc @FacingOurRisk https://t.co/ObdXzC1Ggc

[Elizabeth Kuiper @kuiper_em]

Without appropriate incentives for pharma companies, innovations risk dying on the vine; https://t.co/tmtbRvrhTr @EFPIA

[Larry Green (Ablexis) @AblexisLarry]

Want to learn about selecting an antibody discovery platform? Join our webinar on November 8th! Link below:
https://t.co/5xdW73AIQt

[Larry Green (Ablexis) @AblexisLarry]

Another great licensing partnership, this time with Voyager Therapeutics. Read the full release here: https://t.co/0uwoha5ZrX

[Larry Green (Ablexis) @AblexisLarry]

Proud to announce this licensing agreement between Ablexis and Memorial Sloan Kettering Cancer Center @sloan_kettering https://t.co/cO9B19rLvM